Vedolizumab-5014: Incidence of adverse events of special interest in patients with Crohn’s disease or ulcerative colitis treated with Entyvio as compared to anti-TNF-alpha agents First published 09/02/2017 Last updated 02/04/2024 EU PAS number:EUPAS14135 Study Finalised